FOLH1 and prostate cancer: Advances in metabolic imaging with 18F-choline (FCH) and, more recently, 68Ga-PSMA PET/CT have revolutionized the biochemical recurrence (BR) prostate cancer imaging assessment and allowed the emergence of the oligometastatic disease concept.